MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.85M | 30.88M | 30.60M | 28.71M | 27.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.85M | 30.88M | 30.60M | 28.71M | 27.86M |
| Cost of Revenue | 21.38M | 20.23M | 20.69M | 18.16M | 16.43M |
| Gross Profit | 10.47M | 10.65M | 9.90M | 10.55M | 11.43M |
| SG&A Expenses | 15.54M | 14.70M | 16.18M | 15.45M | 16.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -112.50K | -32.00K | -54.30K | 76.80K | -106.30K |
| Total Operating Expenses | 37.04M | 35.11M | 37.03M | 33.95M | 32.65M |
| Operating Income | -5.19M | -4.23M | -6.43M | -5.25M | -4.79M |
| Income Before Tax | -6.26M | -5.42M | -7.83M | -8.85M | -10.04M |
| Income Tax Expenses | -- | -- | -- | -200.70K | -202.90K |
| Earnings from Continuing Operations | -6.26 | -5.42 | -7.83 | -8.65 | -9.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.26M | -5.42M | -7.83M | -8.65M | -9.84M |
| EBIT | -5.19M | -4.23M | -6.43M | -5.25M | -4.79M |
| EBITDA | -3.83M | -2.64M | -4.54M | -3.30M | -2.76M |
| EPS Basic | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.65B | 1.64B | 1.63B | 1.60B | 1.58B |
| Average Diluted Shares Outstanding | 1.65B | 1.64B | 1.63B | 1.60B | 1.58B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |